ObsEva (NASDAQ:OBSV) has been given a $25.00 price objective by HC Wainwright in a note issued to investors on Thursday. The brokerage currently has a “buy” rating on the stock. HC Wainwright’s price objective would suggest a potential upside of 155.62% from the stock’s previous close.
A number of other equities research analysts also recently issued reports on the stock. Zacks Investment Research downgraded shares of ObsEva from a “buy” rating to a “hold” rating in a research note on Tuesday, December 19th. BMO Capital Markets began coverage on shares of ObsEva in a research note on Monday, December 4th. They issued an “outperform” rating and a $20.00 price target on the stock. Royal Bank of Canada reissued a “buy” rating and issued a $22.00 price target on shares of ObsEva in a research note on Thursday, November 2nd. Finally, Credit Suisse Group began coverage on shares of ObsEva in a research note on Monday, October 9th. They set an “outperform” rating and a $16.00 target price on the stock. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the stock. ObsEva presently has a consensus rating of “Buy” and an average target price of $19.00.
Shares of ObsEva (NASDAQ:OBSV) opened at $9.78 on Thursday. The stock has a market cap of $371.31 and a P/E ratio of -4.49. ObsEva has a 52 week low of $5.00 and a 52 week high of $14.69.
A number of institutional investors and hedge funds have recently made changes to their positions in the stock. VHCP Management II LLC increased its stake in ObsEva by 834.2% during the 3rd quarter. VHCP Management II LLC now owns 1,401,343 shares of the company’s stock worth $11,407,000 after buying an additional 1,251,343 shares during the period. Abingworth LLP purchased a new stake in ObsEva during the 3rd quarter worth approximately $3,480,000. Sphera Funds Management LTD. increased its stake in ObsEva by 12.4% during the 3rd quarter. Sphera Funds Management LTD. now owns 260,197 shares of the company’s stock worth $2,118,000 after buying an additional 28,700 shares during the period. Sectoral Asset Management Inc increased its stake in ObsEva by 181.9% during the 2nd quarter. Sectoral Asset Management Inc now owns 212,831 shares of the company’s stock worth $1,820,000 after buying an additional 137,331 shares during the period. Finally, Iguana Healthcare Management LLC increased its stake in ObsEva by 66.7% during the 3rd quarter. Iguana Healthcare Management LLC now owns 50,000 shares of the company’s stock worth $407,000 after buying an additional 20,000 shares during the period. 35.91% of the stock is currently owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION WARNING: This article was first reported by Ticker Report and is the property of of Ticker Report. If you are viewing this article on another site, it was copied illegally and reposted in violation of US & international copyright & trademark laws. The correct version of this article can be viewed at https://www.tickerreport.com/banking-finance/3128182/obseva-obsv-given-a-25-00-price-target-by-hc-wainwright-analysts.html.
ObsEva Company Profile
Obseva SA is a Switzerland-based company active in the pharmaceutical and medical research sector. The Company develops oral compounds to treat women’s reproductive health conditions from conception to birth. Its pipeline includes three product candidates: OBE2109 is an oral gonadotropin-releasing hormone (GnRH) receptor antagonist that binds to and blocks the endogenous GnRH from activating its pituitary receptors, which reduces estrogen production by the ovaries and leads to amenorrhea.
Receive News & Ratings for ObsEva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ObsEva and related companies with MarketBeat.com's FREE daily email newsletter.